Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies
SCIE
SCOPUS
- Title
- Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies
- Authors
- YUN, EUN JIN; Zhou, Jiancheng; Luo, Junhang; Wu, Kaijie; Kapur, Payal; Pong, Rey-Chen; Du, Yuefeng; Wang, Bin; Authement, C; Hernandez, Elizabeth; Yang, Jichen; Xiao, Guanghua; Cha Tai-Lung; Wu, His-Chin; Wu, Dapeng; Margulis, Vitaly; Lotan, Yair; Brugarolas, Jame; He, Dalin; Hsieh, Jer-Tsong
- Date Issued
- 2016-09-01
- Publisher
- NATURE PUBLISHING GROUP
- Abstract
- Targeted therapies using small-molecule inhibitors (SMIs) are commonly used in metastatic renal cell cancer (mRCC) patients; patients often develop drug resistance and eventually succumb to disease. Currently, understanding of mechanisms leading to SMIs resistance and any identifiable predictive marker(s) are still lacking. We discovered that DAB2IP, a novel Ras-GTPase-activating protein, was frequently epigenetically silenced in RCC, and DAB2IP loss was correlated with the overall survival of RCC patients. Loss of DAB2IP in RCC cells enhances their sensitivities to growth factor stimulation and resistances to SMI (such as mammalian target of rapamycin (mTOR) inhibitors). Mechanistically, loss of DAB2IP results in the activation of extracellular signal-regulated kinase/RSK1 and phosphoinositide-3 kinase/mTOR pathway, which synergizes the induction of hypoxia-inducible factor (HIF)-2 alpha expression. Consequently, elevated HIF-2 alpha suppresses p21/WAF1 expression that is associated with resistance to mTOR inhibitors. Thus combinatorial targeting both pathways resulted in a synergistic tumor inhibition. DAB2IP appears to be a new prognostic/predictive marker for mRCC patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC.
- Keywords
- ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; BREAST-CANCER; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; RENAL-CARCINOMA; DOWN-REGULATION; ACTIVATION; EXPRESSION
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/39238
- DOI
- 10.1038/onc.2016.4
- ISSN
- 0950-9232
- Article Type
- Article
- Citation
- ONCOGENE, vol. 35, no. 35, page. 4663 - 4674, 2016-09-01
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.